News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Keck Graduate Institute of Applied Life Sciences to Celebrate Rare Disease Day With Orphan Drug Workshop


1/31/2011 7:43:47 AM

CLAREMONT, Calif., Jan. 31, 2011 /PRNewswire/ -- Keck Graduate Institute (KGI) will celebrate Rare Disease Day on Feb. 28 by hosting its second annual workshop with the U.S. Food and Drug Administration (FDA) for pharmaceutical and biotech companies and academics to learn how to write and file an Orphan Drug designation application.

Hosted by KGI's Center for Rare Disease Therapies, the goal of the workshop is to simplify and demystify the application process so more companies and individuals will pursue development of drug therapies and medical devices for people who are suffering from rare diseases. Eighteen applications for rare disease therapies were filed after last year's workshop.

Rare diseases affect nearly 25 million Americans. No treatment is available for most of the 7,000 identified rare diseases, and for those that can be treated the cost to the patient is often prohibitive.

Dr. Tim Cote, director of the FDA's Office of Orphan Products Development, will conduct the workshop in which participants will be guided by FDA officers through the application process. Meetings will be conducted in private rooms to maintain confidentiality. Participants will be able to submit their proposals in person to the FDA at the end of the two-day workshop.

"This is a highly efficient way to get an application done correctly and into the hands of the FDA," said Ian Phillips, PhD, KGI's Norris Professor and director of the Center for Rare Disease Therapies.

The workshop coincides with Rare Disease Day, an international effort to raise awareness about the difficulties of combating rare diseases since, for most patients, drugs and treatments are not available.

The Office of Orphan Products Development offers special incentives to companies to develop these products because there often is little profit in developing a drug for a disease that may afflict a small number of people.

To receive orphan designation, the proposed therapy must target a rare disease (one with a patient population of 200,000 or less), and it must show promise for treatment.

Companies or institutions that have a product for treatment of a rare disease and sufficient data to show it may be promising should send the following information to James Bona, FDA workshop coordinator, at james.bona@fda.hhs.govor fax to 301-847-8621: names of proposed attendees; contact information; proposed orphan product, and the rare disease targeted.

Upon notification of acceptance to the workshop by the FDA, attendees must complete registration for the workshop at: www.kgi.edu/fda_workshop.xml

KGI BackgrounD

Educating the future leaders of the bioscience industry, Keck Graduate Institute (KGI) offers an interdisciplinary graduate education through its Master of Bioscience (MBS), Postdoctoral Professional Masters in Bioscience Management (PPM), Postbaccalaureate Premedical Certificate (PPC), PhD and other academic programs. Using team-based learning and real-world projects, KGI's innovative curriculum seamlessly combines applied life sciences, bioengineering, bioethics and business management. KGI also has a robust research program concentrating on the translation of basic discoveries in the life sciences into applications that can benefit society. KGI is a member of The Claremont Colleges, located in Claremont, California.

Keck Graduate Institute of Applied Life Sciences is dedicated to education and research aimed at translating into practice, for the benefit of society, the power and potential of the life sciences.

SOURCE Keck Graduate Institute (KGI)


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES